Data presented at the 2025 American Society of Clinical Oncology Gastroenterology conference demonstrates high success rates in tumor removal and long-term survival in patients with advanced gastric or gastroesophageal junction (GEJ) cancer treated with a camrelizumab combination.
The treatment, which combines camrelizumab with three chemotherapy drugs (nab-paclitaxel, oxaliplatin, and fluorouracil), was tested in a phase 2 clinical trial called FDZL-001. Here are the key findings:
- 75% of patients achieved complete tumor removal
- 23.1% had a complete disappearance of cancer cells
- 88.5% of patients responded to the treatment
- 98.1% had their disease controlled
After three years:
- 62.8% of patients were still alive
- 56.9% had no cancer progression
This treatment may offer new hope for patients with advanced gastric or GEJ cancer that was previously considered inoperable.
The study included 52 patients, both men and women, with various tumor locations. Some patients also received an additional drug called trastuzumab if their cancer was HER2-positive. While all patients experienced some side effects, most were manageable. The most common side effects included anemia, low white blood cell count, and skin-related issues.
This new treatment combination could provide a valuable option for patients with advanced gastric or GEJ cancer, potentially improving their chances of tumor removal and long-term survival.
About Camrelizumab
Camrelizumab is a type of immune therapy called a “checkpoint inhibitor” – a monoclonal antibody directed against the cell surface programmed death-1 (PD-1, PCD-1) receptor. Camrelizumab binds to and blocks the binding of PD-1 expressed on immune cells and prevents their activation and downstream signaling pathways which restores immune function of cytotoxic T lymphocytes (CTLs) and the cell-mediated immune responses against cancer cells.
More Reading
Diagnosed with Gastric Cancer: 10 Tips on How to Get The Most From Your Doctor
Join the conversation on Cancer Connect!
Reference
Geng Q, Feng W, Huang H, et al. Conversion effects of PD-1 inhibitor camrelizumab (cam) combined with Nab-POF regimen in patients (pts) with initially unresectable locally advanced or limited metastatic gastric or gastroesophageal junction adenocarcinoma: FDZL-001 trial. J Clin Oncol. 2025;43(4):334. doi:10.1200/JCO.2025.43.4_suppl.334
